MedTrace Logo

Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects

NCT06671873 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-07-31

No results posted yet for this study

Summary

To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of \[14C\]HMPL-306

Conditions

  • Mass Balance Study

Interventions

DRUG

100 µCi [14C] HMPL-306

D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Wei Zhao, offices director · The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2025-02-28
Completion
2025-07-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671873 on ClinicalTrials.gov